Results 161 to 170 of about 1,679,672 (353)
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens +6 more
wiley +1 more source
New hydrogen storage/phase change materials and their thermochemistry studies
New hydrogen storage phase change materials and their thermochemistry ...
孙立贤
core
Construction of a predictive model for cross scale graphene composite phase change materials based on machine learning and study on its heat transfer mechanism [PDF]
Ying Xu +4 more
openalex +1 more source
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source
Finding novel vulnerabilities of hypomorphic BRCA1 alleles
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder +10 more
wiley +1 more source
OBJECTIVES: 1. Introduce shape-stabilized phase change materials (SSPCMs) 2. Evaluate the limitations of conventional PCMs 3. Explore mechanisms of shape stabilization 4. Assess advantages of SSPCMs over conventional PCMs 5.
Ismail, Mohammad +3 more
core
Fabrication and thermal performance of ternary fatty acid/expanded graphite form-stable composite phase change materials. [PDF]
Zhou D, Yuan J, Zhou F, Liu Y.
europepmc +1 more source
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi +14 more
wiley +1 more source
Advances in Phase Change Materials for Thermal Energy Storage and Management: Challenges and Enhancement Strategies. [PDF]
Muhabie AA, Mengesha WG, Yang X.
europepmc +1 more source

